# A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

> **NCT05207670** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 320 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab (Cohorts A-C)
- **DRUG:** Mosunetuzumab (Cohorts D-E)
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05207670
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05207670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05207670, "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05207670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*